Welcome to Biotage—Medicinal and Analytical Chemistry, Process Development

Interim report January - June 2010

Biotage AB (publ) - disclosure notice of substantial holding of shares

Biotage appoints Anders Wikström as Vice President of Operations and Anthony Rees as Chief Scientific Officer

Biotage Introduces Resolux™ Peptides Purification HPLC Columns

New Isolera™ UV-VIS Flash Purification System delivers widest wavelength range available to chemists (Copy)

Biotage Launches New Isolera™ ELS Detector, Helps Isolate Virtually Any Compound

Biotage Introduces Highly-Selective ExploraSep 96-Well Screening Plates based on Molecularly Imprinted Polymers

Biotage Introduces Highly-Selective AFFINILUTE MIP

European Peptide SymposiumBiotage are Gold Sponsors.
5th - 9th September
Copenhagen, DenmarkILMAC 201021st - 24th September
Basel, SwitzerlandAOACAugust 27-28
Orlando, FL27th Montreux Symposium on LC/MS 10th - 12th November
Montreux, SwitzerlandThe 3rd EBF Open Symposium 1st - 3rd December
Barcelona, Spain

Corporate Governace Introduction Biotage applies the Swedish Companies Act, the rules and regulations that follow from the Company’s Listing Agreement with the NASDAQ OMX Nordic Exchange. the Swedish Finance Inspection rules and the Swedish Code of Corporate Governance (the ”Code”) In addition hereto, the Company applies the provisions of the Articles of the Association and recommendations issued from relevant Swedish organizations. The Code applies to all companies listed at NASDAQ OMX Nordic Exchange Stockholm or NGM Equity as of 1 July 2008.		Introduction General Meeting Nomination Committee Board of Directors Compensation Committee Audit Committee Auditor Group Management Annual General Meeting Corporate Governance Report 15 Largest Owners Incentive Programs Articles of Association
Print page